Weidemann B, Brade H, Rietschel E T, Dziarski R, Bazil V, Kusumoto S, Flad H D, Ulmer A J
Department of Immunology and Cell Biology, Forschungsinstitut Borstel, Germany.
Infect Immun. 1994 Nov;62(11):4709-15. doi: 10.1128/iai.62.11.4709-4715.1994.
We have investigated the interaction of soluble peptidoglycan (sPG), in comparison with lipopolysaccharide (LPS), with human mononuclear cells (MNC) by determining the capacity of sPG to induce interleukin-6 (IL-6) and IL-1 release. In addition, we investigated the modulation of their interaction by anti-CD14 monoclonal antibody and by partial structures of LPS. We found that sPG, like LPS, was able to induce IL-6 and IL-1 production by MNC. However, dose-response experiments revealed that at least 3,000 ng of sPG per ml was necessary for induction, whereas the optimal LPS concentration was 1 ng/ml. Anti-CD14 monoclonal antibody reduced sPG- and LPS-induced IL-6 and IL-1 production. Moreover, partial structures of LPS were able to reduce monokine production induced by sPG and LPS. We conclude that sPG constitutes, like LPS, an inflammatory cytokine inducer and that CD14 is involved in the activation of human monocytes not only by LPS but also by sPG.
我们通过测定可溶性肽聚糖（sPG）诱导白细胞介素-6（IL-6）和白细胞介素-1释放的能力，研究了其与脂多糖（LPS）相比，与人单核细胞（MNC）的相互作用。此外，我们还研究了抗CD14单克隆抗体和LPS部分结构对它们相互作用的调节。我们发现，sPG与LPS一样，能够诱导MNC产生IL-6和IL-1。然而，剂量反应实验表明，每毫升至少需要3000纳克的sPG才能诱导产生，而LPS的最佳浓度为1纳克/毫升。抗CD14单克隆抗体减少了sPG和LPS诱导的IL-6和IL-1的产生。此外，LPS的部分结构能够减少sPG和LPS诱导的单核因子产生。我们得出结论，sPG与LPS一样，是一种炎性细胞因子诱导剂，并且CD14不仅参与LPS激活人单核细胞，也参与sPG激活人单核细胞。
